Tanezumab is a monoclonal antibody that specifically targets and blocks nerve growth factor (NGF), a protein involved in the regulation of pain signaling. This targeted approach helps to alleviate pain by reducing the activity of NGF, which is implicated in the development and maintenance of chronic pain conditions.
Used in Pharmaceutical Industry:
Tanezumab is used as a therapeutic agent for the treatment of chronic pain conditions that are refractory to conventional pain medications. Its application is based on its ability to block the action of NGF, thereby reducing pain signaling and improving the quality of life for patients suffering from chronic pain.
Used in Pain Management:
Tanezumab is used as a pain reliever for conditions such as osteoarthritis and chronic lower back pain. By inhibiting the effects of NGF, Tanezumab helps to decrease the intensity of pain and enhance mobility in patients with these chronic conditions, offering an alternative treatment option for those who do not respond well to traditional pain management strategies.
Used in Research and Development:
In addition to its clinical applications, Tanezumab is also utilized in research settings to further understand the role of NGF in pain perception and the development of chronic pain. This research can potentially lead to the discovery of new therapeutic targets and the development of novel pain management treatments.
Used in Pharmaceutical Industry:
Tanezumab is used as a therapeutic agent for the treatment of chronic pain conditions that are refractory to conventional pain medications. Its application is based on its ability to block the action of NGF, thereby reducing pain signaling and improving the quality of life for patients suffering from chronic pain.
Used in Pain Management:
Tanezumab is used as a pain reliever for conditions such as osteoarthritis and chronic lower back pain. By inhibiting the effects of NGF, Tanezumab helps to decrease the intensity of pain and enhance mobility in patients with these chronic conditions, offering an alternative treatment option for those who do not respond well to traditional pain management strategies.
Used in Research and Development:
In addition to its clinical applications, Tanezumab is also utilized in research settings to further understand the role of NGF in pain perception and the development of chronic pain. This research can potentially lead to the discovery of new therapeutic targets and the development of novel pain management treatments.
880266-57-9
Post Buying Request-
-
Basic information
- Product Name: Tanezumab
- Synonyms: tanezumab
- CAS NO:880266-57-9
- Molecular Formula:
- Molecular Weight: 0
- EINECS: N/A
- Product Categories: N/A
-
Chemical Properties
- Melting Point: N/A
- Boiling Point: N/A
- Flash Point: N/A
- Appearance: /
- Density: N/A
- Refractive Index: N/A
- Storage Temp.: N/A
- Solubility: N/A
- CAS DataBase Reference: Tanezumab(CAS DataBase Reference)
- NIST Chemistry Reference: Tanezumab(880266-57-9)
- EPA Substance Registry System: Tanezumab(880266-57-9)
-
Safety Data
- Hazard Codes: N/A
- Statements: N/A
- Safety Statements: N/A
- WGK Germany:
- RTECS:
- HazardClass: N/A
- PackingGroup: N/A
- Hazardous Substances Data: 880266-57-9(Hazardous Substances Data)
880266-57-9 Suppliers
Recommended suppliers
880266-57-9 Usage
Check Digit Verification of cas no
The CAS Registry Mumber 880266-57-9 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,8,0,2,6 and 6 respectively; the second part has 2 digits, 5 and 7 respectively.Calculate Digit Verification of CAS Registry Number 880266-57:
(8*8)+(7*8)+(6*0)+(5*2)+(4*6)+(3*6)+(2*5)+(1*7)=189
189 % 10 = 9
So 880266-57-9 is a valid CAS Registry Number.
880266-57-9Upstream product
880266-57-9Downstream Products
Post a RFQ
1
What can I do for you?
Get Best Price
Get Best Price for 880266-57-9
Tanezumab
